{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T13:00:14Z","timestamp":1780750814054,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Department of Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University Hospital and the Department of Clinical Pharmacy and Biochemistry at the Freie Universitaet Berlin"},{"DOI":"10.13039\/501100007537","name":"Freie Universit\u00e4t Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40262-022-01175-6","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T16:02:46Z","timestamp":1664899366000},"page":"1595-1607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0507-7130","authenticated-orcid":false,"given":"Yomna M.","family":"Nassar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-607X","authenticated-orcid":false,"given":"Robin","family":"Michelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Gottwalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas D.","family":"Meid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-3914","authenticated-orcid":false,"given":"Wilhelm","family":"Huisinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0672-6876","authenticated-orcid":false,"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-133X","authenticated-orcid":false,"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"1175_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41\u201357. https:\/\/doi.org\/10.2165\/00003088-200038010-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1175_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0009-9236(96)90162-9","volume":"60","author":"MF Paine","year":"1996","unstructured":"Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther. 1996;60:14\u201324. https:\/\/doi.org\/10.1016\/S0009-9236(96)90162-9.","journal-title":"Clin Pharmacol Ther"},{"key":"1175_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1146\/annurev.pharmtox.38.1.389","volume":"38","author":"KE Thummel","year":"1998","unstructured":"Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998;38:389\u2013430. https:\/\/doi.org\/10.1146\/annurev.pharmtox.38.1.389.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1175_CR4","doi-asserted-by":"publisher","unstructured":"Nagar S, Argikar UA, Tweedie DJ. Reversible mechanisms of enzyme inhibition and resulting clinical significance. In: Enzyme kinetics in drug metabolism: fundamentals and applications, Vol. 1113. Totowa: Humana Press; 2014; pp 37\u201356. doi: https:\/\/doi.org\/10.1007\/978-1-62703-758-7_1.","DOI":"10.1007\/978-1-62703-758-7_1"},{"key":"1175_CR5","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00228-013-1530-8","volume":"69","author":"C Eichbaum","year":"2013","unstructured":"Eichbaum C, Cortese M, Blank A, Burhenne J, Mikus G. Concentration effect relationship of CYP3A inhibition by ritonavir in humans. Eur J Clin Pharmacol. 2013;69:1795\u2013800. https:\/\/doi.org\/10.1007\/s00228-013-1530-8.","journal-title":"Eur J Clin Pharmacol"},{"key":"1175_CR6","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions 2010. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf. [Accessed 25 May 2021]."},{"key":"1175_CR7","unstructured":"US Food and Drug Administration. Guidance for industry: clinical drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions. 2020:1\u201327. Available from: https:\/\/www.fda.gov\/media\/134581\/download\/. [Accessed 25 May 2021]."},{"key":"1175_CR8","unstructured":"Pharmaceuticals and Medical Devices Agency. Guideline on drug interaction for drug development and appropriate provision of information Title 2019. Available from: https:\/\/www.pmda.go.jp\/files\/000228122.pdf. [Accessed 19 Jul 2022]."},{"key":"1175_CR9","first-page":"89","volume":"36","author":"T Kronbach","year":"1989","unstructured":"Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol. 1989;36:89\u201396.","journal-title":"Mol Pharmacol"},{"key":"1175_CR10","first-page":"549","volume":"271","author":"KE Thummel","year":"1994","unstructured":"Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther. 1994;271:549\u201356.","journal-title":"J Pharmacol Exp Ther."},{"key":"1175_CR11","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2011.164","volume":"90","author":"S Katzenmaier","year":"2011","unstructured":"Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther. 2011;90:666\u201373. https:\/\/doi.org\/10.1038\/clpt.2011.164.","journal-title":"Clin Pharmacol Ther"},{"key":"1175_CR12","unstructured":"Roche. Dormicum Injektionsl\u00f6sung 2019. Available from: https:\/\/www.roche.com.sg\/content\/dam\/rochexx\/roche-com-sg\/documents\/product-page\/DormicumInjPIApr 2019.pdf. [Accessed 25 May 2021]."},{"key":"1175_CR13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/clpt.2013.27","volume":"93","author":"B Halama","year":"2013","unstructured":"Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther. 2013;93:564\u201371. https:\/\/doi.org\/10.1038\/clpt.2013.27.","journal-title":"Clin Pharmacol Ther"},{"key":"1175_CR14","doi-asserted-by":"publisher","first-page":"43S","DOI":"10.1111\/j.1365-2125.1983.tb02270.x","volume":"16","author":"P Heizmann","year":"1983","unstructured":"Heizmann P, Eckert M, Ziegler W. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol. 1983;16:43S-S49. https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb02270.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1175_CR15","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00216-011-5675-y","volume":"402","author":"J Burhenne","year":"2012","unstructured":"Burhenne J, Halama B, Maurer M, Riedel KD, Hohmann N, Mikus G, et al. Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1\u2032-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem. 2012;402:2439\u201350. https:\/\/doi.org\/10.1007\/s00216-011-5675-y.","journal-title":"Anal Bioanal Chem"},{"key":"1175_CR16","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40262-016-0416-1","volume":"55","author":"N Hohmann","year":"2016","unstructured":"Hohmann N, Kocheise F, Carls A, Burhenne J, Weiss J, Haefeli WE, et al. Dose-dependent bioavailability and CYP3A inhibition contribute to non-linear pharmacokinetics of voriconazole. Clin Pharmacokinet. 2016;55:1535\u201345. https:\/\/doi.org\/10.1007\/s40262-016-0416-1.","journal-title":"Clin Pharmacokinet"},{"key":"1175_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO. Xpose - An S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1998;58:51\u201364. https:\/\/doi.org\/10.1016\/S0169-2607(98)00067-4.","journal-title":"Comput Methods Programs Biomed"},{"key":"1175_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/00003088-200847100-00004","volume":"47","author":"Y Ohno","year":"2008","unstructured":"Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet. 2008;47:669\u201380. https:\/\/doi.org\/10.2165\/00003088-200847100-00004.","journal-title":"Clin Pharmacokinet"},{"key":"1175_CR19","unstructured":"Karlsson MO, Holford N. A tutorial on visual predictive checks [abstract 1434]. Abstract. Annual Meeting Population Approach Group 17, Marseille, France. 2008: p.17. Available from: www.page-meeting.org\/?abstract=1434. [Accessed 31 Aug 2022]."},{"key":"1175_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/9781118784860.ch8","volume":"2","author":"JS Owen","year":"2014","unstructured":"Owen JS, Fiedler-Kelly J. Introduction to model evaluation. Introduction to population Pharmacokinetics\/pharmacodynamics. Anal Nonlinear Mix Eff Model. 2014;2:212\u201331. https:\/\/doi.org\/10.1002\/9781118784860.ch8.","journal-title":"Anal Nonlinear Mix Eff Model."},{"key":"1175_CR21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","volume":"43","author":"AG Dosne","year":"2016","unstructured":"Dosne AG, Bergstrand M, Harling K, Karlsson MO. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. J Pharmacokinet Pharmacodyn. 2016;43:583\u201396. https:\/\/doi.org\/10.1007\/s10928-016-9487-8.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1175_CR22","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/jcph.1125","volume":"58","author":"J Yang","year":"2018","unstructured":"Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, et al. Midazolam single time point concentrations to estimate exposure and cytochrome P450 (CYP) 3A constitutive activity utilizing limited sampling strategy with a population pharmacokinetic approach. J Clin Pharmacol. 2018;58:1205\u201313. https:\/\/doi.org\/10.1002\/jcph.1125.","journal-title":"J Clin Pharmacol"},{"key":"1175_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10928-020-09704-1","volume":"47","author":"ST Wiebe","year":"2020","unstructured":"Wiebe ST, Meid AD, Mikus G. Composite midazolam and 1\u2032-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity. J Pharmacokinet Pharmacodyn. 2020;47:527\u201342. https:\/\/doi.org\/10.1007\/s10928-020-09704-1.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1175_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00558225","volume":"37","author":"PO Maitre","year":"1989","unstructured":"Maitre PO, Funk B, Crevoisier C, Ha HR. Pharmacokinetics of midazolam in patients recovering from cardiac surgery. Eur J Clin Pharmacol. 1989;37:161\u20136. https:\/\/doi.org\/10.1007\/BF00558225.","journal-title":"Eur J Clin Pharmacol"},{"key":"1175_CR25","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/jcph.318","volume":"54","author":"D Tomalik-Scharte","year":"2014","unstructured":"Tomalik-Scharte D, Suleiman AA, Frechen S, Kraus D, Kerkweg U, Rokitta D, et al. Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam. J Clin Pharmacol. 2014;54:1162\u20139. https:\/\/doi.org\/10.1002\/jcph.318.","journal-title":"J Clin Pharmacol"},{"key":"1175_CR26","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/bcp.12693","volume":"80","author":"A Van Rongen","year":"2015","unstructured":"Van Rongen A, Vaughns JD, Moorthy GS, Barrett JS, Knibbe CAJ, Van Den Anker JN. Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents. Br J Clin Pharmacol. 2015;80:1185\u201396. https:\/\/doi.org\/10.1111\/bcp.12693.","journal-title":"Br J Clin Pharmacol"},{"key":"1175_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1046\/j.1365-2125.2000.00104.x","volume":"49","author":"MA Hotz","year":"2000","unstructured":"Hotz MA, Ritz R, Linder L, Scollo-Lavizzari G, Haefeli WE. Auditory and electroencephalographic effects of midazolam and \u03b1-hydroxy-midazolam in healthy subjects. Br J Clin Pharmacol. 2000;49:72\u20139. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00104.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1175_CR28","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/cpt.1828","volume":"108","author":"JK Sodhi","year":"2020","unstructured":"Sodhi JK, Benet LZ. A simple methodology to differentiate changes in bioavailability from changes in clearance following oral dosing of metabolized drugs. Clin Pharmacol Ther. 2020;108:306\u201315. https:\/\/doi.org\/10.1002\/cpt.1828.","journal-title":"Clin Pharmacol Ther"},{"key":"1175_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s40262-013-0070-9","volume":"52","author":"S Frechen","year":"2013","unstructured":"Frechen S, Junge L, Saari TI, Suleiman AA, Rokitta D, Neuvonen PJ, et al. A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole. Clin Pharmacokinet. 2013;52:763\u201381. https:\/\/doi.org\/10.1007\/s40262-013-0070-9.","journal-title":"Clin Pharmacokinet"},{"key":"1175_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.clpt.2005.12.305","volume":"79","author":"TI Saari","year":"2006","unstructured":"Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther. 2006;79:362\u201370. https:\/\/doi.org\/10.1016\/j.clpt.2005.12.305.","journal-title":"Clin Pharmacol Ther"},{"key":"1175_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/03602532.2019.1632888","volume":"51","author":"J Schulz","year":"2019","unstructured":"Schulz J, Kluwe F, Mikus G, Michelet R, Kloft C. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metab Rev. 2019;51:247\u201365. https:\/\/doi.org\/10.1080\/03602532.2019.1632888.","journal-title":"Drug Metab Rev"},{"key":"1175_CR32","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/jcph.879","volume":"57","author":"G Mikus","year":"2017","unstructured":"Mikus G, Heinrich T, B\u00f6digheimer J, R\u00f6der C, Matthee AK, Weiss J, et al. Semisimultaneous midazolam administration to evaluate the time course of CYP3A activation by a single oral dose of efavirenz. J Clin Pharmacol. 2017;57:899\u2013905. https:\/\/doi.org\/10.1002\/jcph.879.","journal-title":"J Clin Pharmacol"},{"key":"1175_CR33","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1124\/dmd.111.043844","volume":"40","author":"A Keubler","year":"2012","unstructured":"Keubler A, Weiss J, Haefeli WE, Mikus G, Burhenne J. Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1\u2032-hydroxylation in vitro. Drug Metab Dispos. 2012;40:1178\u201382. https:\/\/doi.org\/10.1124\/dmd.111.043844.","journal-title":"Drug Metab Dispos"},{"key":"1175_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070330","volume":"8","author":"F Yamashita","year":"2013","unstructured":"Yamashita F, Sasa Y, Yoshida S, Hisaka A, Asai Y, Kitano H, et al. Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data. PLoS ONE. 2013;8: e70330. https:\/\/doi.org\/10.1371\/journal.pone.0070330.","journal-title":"PLoS ONE"},{"key":"1175_CR35","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s11095-017-2168-5","volume":"34","author":"T Yoshikado","year":"2017","unstructured":"Yoshikado T, Maeda K, Furihata S, Terashima H, Nakayama T, Ishigame K, et al. A clinical cassette dosing study for evaluating the contribution of hepatic OATPs and CYP3A to drug-drug interactions. Pharm Res. 2017;34:1570\u201383. https:\/\/doi.org\/10.1007\/s11095-017-2168-5.","journal-title":"Pharm Res"},{"key":"1175_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0009-9236(96)90018-1","volume":"59","author":"JT Backman","year":"1996","unstructured":"Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996;59:7\u201313. https:\/\/doi.org\/10.1016\/S0009-9236(96)90018-1.","journal-title":"Clin Pharmacol Ther"},{"key":"1175_CR37","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3109\/00498250701620700","volume":"37","author":"HJ Einolf","year":"2007","unstructured":"Einolf HJ. Comparison of different approaches to predict metabolic drug\u2013drug interactions. Xenobiotica. 2007;37:1257\u201394. https:\/\/doi.org\/10.3109\/00498250701620700.","journal-title":"Xenobiotica"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01175-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01175-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01175-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T02:20:09Z","timestamp":1668219609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01175-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01175-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"assertion":[{"value":"21 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. This trial and data analysis were funded by internal resources of the Department of Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University Hospital and the Department of Clinical Pharmacy and Biochemistry at the Freie Universitaet Berlin. No medical writing support was used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yomna M. Nassar, Nicolas Hohmann, Katharina Gottwald, Robin Michelet, Andreas D. Meid, J\u00fcrgen Burhenne, Walter E. Haefeli, and Gerd Mikus declare that they have no conflicts of interest that might be relevant to the content of this article. Charlotte Kloft and Wilhelm Huisinga report grants from an industry consortium (AbbVie Deutschland GmbH & Co. KG, AstraZeneca, Boehringer Ingelheim Pharma GmbH\u00a0&\u00a0Co.KG, Gr\u00fcnenthal GmbH, F. Hoffmann-La Roche Ltd., Merck KGaA, and Sanofi) for the PharMetrX PhD program. Charlotte Kloft reports a grant from the European Commission for Innovative Medicines Initiative-Joint Undertaking (\u2018DDMoRe\u2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with Good Clinical Practice (ICH-GCP) guidelines and the ethical standards of the current Declaration of Helsinki. The trial protocol (EudraCT 2013-004869-14) was approved by the responsible Ethics Committee of the Medical Faculty of Heidelberg University and the competent authority (BfArM, Bonn, Germany).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All included volunteers gave their written informed consent prior to any study procedures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The NONMEM model code is available in the ESM.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"NH, KG, WEH, and GM designed the clinical study conception and conducted the study; JB performed the midazolam bioanalytical analysis; YMN and ADM conducted the data analyses; YMN, RM, GM, and CK thoroughly discussed the data analysis and were involved in the interpretation of results; RM, WH, and CK provided methodological support; WH, GM, and CK provided supervision; the first version of the manuscript was drafted by YMN; all authors critically reviewed, edited, and commented on previous versions of the manuscript, and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}